Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis
Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients w...
Gespeichert in:
| Veröffentlicht in: | High Blood Pressure & Cardiovascular Prevention 2023-05, Vol.30 (3), p.207-218 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 218 |
|---|---|
| container_issue | 3 |
| container_start_page | 207 |
| container_title | High Blood Pressure & Cardiovascular Prevention |
| container_volume | 30 |
| creator | Almarjan, Amjaad Ibrahim Almarjan, Sara Abdulaziz Masoud, Ahmed Taher |
| description | Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients with hypertension.
To compare the efficacy and safety of sacubitril/valsartan versus olmesartan in patients with hypertension.
This study follows the guidelines of the Cochrane Handbook. We searched MEDLINE, Cochrane Central, Scopus, and Web of Science databases for relevant clinical trials. We extracted outcome endpoints regarding mean ambulatory systolic/diastolic blood pressure (maSBP/maDBP), mean sitting systolic/diastolic blood pressure (msSBP/msDBP), mean ambulatory/mean sitting pulse pressure (maPP/msPP), the proportion of patients achieving blood pressure control ( |
| doi_str_mv | 10.1007/s40292-023-00572-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2921221054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2921221054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2907-bbf729c9769865c49ed4d26644eee21c16a5bd4002c9317d48851beb36294fa33</originalsourceid><addsrcrecordid>eNpNUclOwzAQtRCI_Qc4IEucQ23HiWtuVVsoEgjEdrWcZCKMshSPS9Wv4JcxtCBOM6P35s3yCDnh7JwzpgYomdAiYSJNGMuUSNQW2edc6YTrYbb9L98jB4hvjAmlpd4le6liEWJ8n3xOXF2Dhy7QSY-AtK_poy0XhQveNYMX26D1wXZ03Ldz66GiSxde6V3TwgZwHb23wUUFXGNTxFg429DZag4-QIeu7y7oiD6uMEAbySV9gA8HS2q7it5CsMmos80KHR6RnTrOhONNPCTPl9On8Sy5ubu6Ho9uklJoppKiqJXQpVa5HuZZKTVUshJ5LiUACF7y3GZFJePFpU65quRwmPECijQXWtY2TQ_J2Vp37vv3BWAwb_3CxyXQxJ9yITjLZGSJNav0PaKH2sy9a61fGc7Mtwdm7YGJHpgfD4yKTacb6UXRQvXX8vv09AvtJoNh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2921221054</pqid></control><display><type>article</type><title>Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Almarjan, Amjaad Ibrahim ; Almarjan, Sara Abdulaziz ; Masoud, Ahmed Taher</creator><creatorcontrib>Almarjan, Amjaad Ibrahim ; Almarjan, Sara Abdulaziz ; Masoud, Ahmed Taher</creatorcontrib><description>Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients with hypertension.
To compare the efficacy and safety of sacubitril/valsartan versus olmesartan in patients with hypertension.
This study follows the guidelines of the Cochrane Handbook. We searched MEDLINE, Cochrane Central, Scopus, and Web of Science databases for relevant clinical trials. We extracted outcome endpoints regarding mean ambulatory systolic/diastolic blood pressure (maSBP/maDBP), mean sitting systolic/diastolic blood pressure (msSBP/msDBP), mean ambulatory/mean sitting pulse pressure (maPP/msPP), the proportion of patients achieving blood pressure control (< 140/90 mmHg), and adverse events. We used Review Manager Software for the conduction of the analysis of this study. The effect estimates of the studies were pooled as Mean difference or risk ratio and 95% confidence interval. We also conducted a subgroup analysis based on the dose of sacubitril/valsartan.
A total of six clinical trials were included. The studies showed an overall low risk of bias. The pooled effect estimate revealed that sacubitril/valsartan significantly reduces maSBP, maDBP, maPP, msSBP, and msDBP measurements compared with olmesartan (p < 0.001). A significantly higher portion of patients achieved blood pressure control in the sacubitril/valsartan group (p < 0.001). The test of subgroup difference showed that 400 mg dose is significantly more effective than 200 mg dose in reducing maSBP. Regarding the safety profile, olmesartan was associated with more side effects due to drug discontinuation and more serious side effects.
Sacubitril/valsartan or LCZ696 is more effective and safer than olmesartan for controlling blood pressure in patients with hypertension.</description><identifier>ISSN: 1179-1985</identifier><identifier>ISSN: 1120-9879</identifier><identifier>EISSN: 1179-1985</identifier><identifier>DOI: 10.1007/s40292-023-00572-7</identifier><identifier>PMID: 37017901</identifier><language>eng</language><publisher>New Zealand: Springer Nature B.V</publisher><subject>Aminobutyrates - adverse effects ; Angiotensin II Type 1 Receptor Blockers - adverse effects ; Angiotensin Receptor Antagonists - adverse effects ; Antihypertensives ; Blood Pressure ; Clinical outcomes ; Clinical trials ; Comparative analysis ; Demographics ; Drug Combinations ; Essential Hypertension ; Humans ; Hypertension ; Hypertension - chemically induced ; Hypertension - diagnosis ; Hypertension - drug therapy ; Pharmacovigilance ; Side effects ; Tetrazoles - adverse effects ; Valsartan - adverse effects</subject><ispartof>High Blood Pressure & Cardiovascular Prevention, 2023-05, Vol.30 (3), p.207-218</ispartof><rights>2023. Italian Society of Hypertension.</rights><rights>Italian Society of Hypertension 2023. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2907-bbf729c9769865c49ed4d26644eee21c16a5bd4002c9317d48851beb36294fa33</citedby><cites>FETCH-LOGICAL-c2907-bbf729c9769865c49ed4d26644eee21c16a5bd4002c9317d48851beb36294fa33</cites><orcidid>0000-0003-4304-6781</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37017901$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Almarjan, Amjaad Ibrahim</creatorcontrib><creatorcontrib>Almarjan, Sara Abdulaziz</creatorcontrib><creatorcontrib>Masoud, Ahmed Taher</creatorcontrib><title>Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis</title><title>High Blood Pressure & Cardiovascular Prevention</title><addtitle>High Blood Press Cardiovasc Prev</addtitle><description>Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients with hypertension.
To compare the efficacy and safety of sacubitril/valsartan versus olmesartan in patients with hypertension.
This study follows the guidelines of the Cochrane Handbook. We searched MEDLINE, Cochrane Central, Scopus, and Web of Science databases for relevant clinical trials. We extracted outcome endpoints regarding mean ambulatory systolic/diastolic blood pressure (maSBP/maDBP), mean sitting systolic/diastolic blood pressure (msSBP/msDBP), mean ambulatory/mean sitting pulse pressure (maPP/msPP), the proportion of patients achieving blood pressure control (< 140/90 mmHg), and adverse events. We used Review Manager Software for the conduction of the analysis of this study. The effect estimates of the studies were pooled as Mean difference or risk ratio and 95% confidence interval. We also conducted a subgroup analysis based on the dose of sacubitril/valsartan.
A total of six clinical trials were included. The studies showed an overall low risk of bias. The pooled effect estimate revealed that sacubitril/valsartan significantly reduces maSBP, maDBP, maPP, msSBP, and msDBP measurements compared with olmesartan (p < 0.001). A significantly higher portion of patients achieved blood pressure control in the sacubitril/valsartan group (p < 0.001). The test of subgroup difference showed that 400 mg dose is significantly more effective than 200 mg dose in reducing maSBP. Regarding the safety profile, olmesartan was associated with more side effects due to drug discontinuation and more serious side effects.
Sacubitril/valsartan or LCZ696 is more effective and safer than olmesartan for controlling blood pressure in patients with hypertension.</description><subject>Aminobutyrates - adverse effects</subject><subject>Angiotensin II Type 1 Receptor Blockers - adverse effects</subject><subject>Angiotensin Receptor Antagonists - adverse effects</subject><subject>Antihypertensives</subject><subject>Blood Pressure</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Demographics</subject><subject>Drug Combinations</subject><subject>Essential Hypertension</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - chemically induced</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - drug therapy</subject><subject>Pharmacovigilance</subject><subject>Side effects</subject><subject>Tetrazoles - adverse effects</subject><subject>Valsartan - adverse effects</subject><issn>1179-1985</issn><issn>1120-9879</issn><issn>1179-1985</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpNUclOwzAQtRCI_Qc4IEucQ23HiWtuVVsoEgjEdrWcZCKMshSPS9Wv4JcxtCBOM6P35s3yCDnh7JwzpgYomdAiYSJNGMuUSNQW2edc6YTrYbb9L98jB4hvjAmlpd4le6liEWJ8n3xOXF2Dhy7QSY-AtK_poy0XhQveNYMX26D1wXZ03Ldz66GiSxde6V3TwgZwHb23wUUFXGNTxFg429DZag4-QIeu7y7oiD6uMEAbySV9gA8HS2q7it5CsMmos80KHR6RnTrOhONNPCTPl9On8Sy5ubu6Ho9uklJoppKiqJXQpVa5HuZZKTVUshJ5LiUACF7y3GZFJePFpU65quRwmPECijQXWtY2TQ_J2Vp37vv3BWAwb_3CxyXQxJ9yITjLZGSJNav0PaKH2sy9a61fGc7Mtwdm7YGJHpgfD4yKTacb6UXRQvXX8vv09AvtJoNh</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Almarjan, Amjaad Ibrahim</creator><creator>Almarjan, Sara Abdulaziz</creator><creator>Masoud, Ahmed Taher</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0003-4304-6781</orcidid></search><sort><creationdate>20230501</creationdate><title>Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis</title><author>Almarjan, Amjaad Ibrahim ; Almarjan, Sara Abdulaziz ; Masoud, Ahmed Taher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2907-bbf729c9769865c49ed4d26644eee21c16a5bd4002c9317d48851beb36294fa33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aminobutyrates - adverse effects</topic><topic>Angiotensin II Type 1 Receptor Blockers - adverse effects</topic><topic>Angiotensin Receptor Antagonists - adverse effects</topic><topic>Antihypertensives</topic><topic>Blood Pressure</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Demographics</topic><topic>Drug Combinations</topic><topic>Essential Hypertension</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - chemically induced</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - drug therapy</topic><topic>Pharmacovigilance</topic><topic>Side effects</topic><topic>Tetrazoles - adverse effects</topic><topic>Valsartan - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Almarjan, Amjaad Ibrahim</creatorcontrib><creatorcontrib>Almarjan, Sara Abdulaziz</creatorcontrib><creatorcontrib>Masoud, Ahmed Taher</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>High Blood Pressure & Cardiovascular Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Almarjan, Amjaad Ibrahim</au><au>Almarjan, Sara Abdulaziz</au><au>Masoud, Ahmed Taher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis</atitle><jtitle>High Blood Pressure & Cardiovascular Prevention</jtitle><addtitle>High Blood Press Cardiovasc Prev</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>30</volume><issue>3</issue><spage>207</spage><epage>218</epage><pages>207-218</pages><issn>1179-1985</issn><issn>1120-9879</issn><eissn>1179-1985</eissn><abstract>Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients with hypertension.
To compare the efficacy and safety of sacubitril/valsartan versus olmesartan in patients with hypertension.
This study follows the guidelines of the Cochrane Handbook. We searched MEDLINE, Cochrane Central, Scopus, and Web of Science databases for relevant clinical trials. We extracted outcome endpoints regarding mean ambulatory systolic/diastolic blood pressure (maSBP/maDBP), mean sitting systolic/diastolic blood pressure (msSBP/msDBP), mean ambulatory/mean sitting pulse pressure (maPP/msPP), the proportion of patients achieving blood pressure control (< 140/90 mmHg), and adverse events. We used Review Manager Software for the conduction of the analysis of this study. The effect estimates of the studies were pooled as Mean difference or risk ratio and 95% confidence interval. We also conducted a subgroup analysis based on the dose of sacubitril/valsartan.
A total of six clinical trials were included. The studies showed an overall low risk of bias. The pooled effect estimate revealed that sacubitril/valsartan significantly reduces maSBP, maDBP, maPP, msSBP, and msDBP measurements compared with olmesartan (p < 0.001). A significantly higher portion of patients achieved blood pressure control in the sacubitril/valsartan group (p < 0.001). The test of subgroup difference showed that 400 mg dose is significantly more effective than 200 mg dose in reducing maSBP. Regarding the safety profile, olmesartan was associated with more side effects due to drug discontinuation and more serious side effects.
Sacubitril/valsartan or LCZ696 is more effective and safer than olmesartan for controlling blood pressure in patients with hypertension.</abstract><cop>New Zealand</cop><pub>Springer Nature B.V</pub><pmid>37017901</pmid><doi>10.1007/s40292-023-00572-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-4304-6781</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-1985 |
| ispartof | High Blood Pressure & Cardiovascular Prevention, 2023-05, Vol.30 (3), p.207-218 |
| issn | 1179-1985 1120-9879 1179-1985 |
| language | eng |
| recordid | cdi_proquest_journals_2921221054 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aminobutyrates - adverse effects Angiotensin II Type 1 Receptor Blockers - adverse effects Angiotensin Receptor Antagonists - adverse effects Antihypertensives Blood Pressure Clinical outcomes Clinical trials Comparative analysis Demographics Drug Combinations Essential Hypertension Humans Hypertension Hypertension - chemically induced Hypertension - diagnosis Hypertension - drug therapy Pharmacovigilance Side effects Tetrazoles - adverse effects Valsartan - adverse effects |
| title | Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A12%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20Doses%20of%20Sacubitril/Valsartan%20Compared%20with%20Olmesartan%20in%20Patients%20with%20Essential%20Hypertension:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=High%20Blood%20Pressure%20&%20Cardiovascular%20Prevention&rft.au=Almarjan,%20Amjaad%20Ibrahim&rft.date=2023-05-01&rft.volume=30&rft.issue=3&rft.spage=207&rft.epage=218&rft.pages=207-218&rft.issn=1179-1985&rft.eissn=1179-1985&rft_id=info:doi/10.1007/s40292-023-00572-7&rft_dat=%3Cproquest_cross%3E2921221054%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2921221054&rft_id=info:pmid/37017901&rfr_iscdi=true |